Negative inotropic effects of recombinant interleukin 2 in patients without left ventricular dysfunction

RA Tio*, J Nieken, EGE de Vries, C Pfeiffer, MJL de Jongste, E Pieper, H Moshage, PC Limburg, NH Mulder

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)

Abstract

Experimental data have shown that rIL2 has negative inotropic properties. This has not been investigated in humans with normal left ventricular function. Seventeen consecutive renal cell carcinoma patients who received rIL2 therapy because of dissemination were analyzed before and after treatment with a low dose of rIL2 subcutaneously. Left ventricular ejection fraction (echocardiography), heart rate variability parameters (24 h electrocardiography), and TNF alpha, IL1 beta and nitric oxide metabolites (NOx) were measured. LVEF decreased from 54 +/- 7 to 50 +/- 6% (mean +/- S.D.; P = 0.012), with a concomitant increase in heart rate from 87 +/- 13 to 94 +/- 13 beats/min (P = 0.031). All frequency domain HRV parameters decreased: the total power from 18.0 +/- 7.9 to 14.0 +/- 5.0 ms (P = 0.001), the low frequency from 10.3 +/- 5.4 to 8.3 +/- 3.4 ms (P = 0.001), and the high frequency from 6.3 +/- 2.6 to 4.5 +/- 1.1 ms (P = 0.001), There was no measurable effect on TNF alpha, IL1 beta concentrations. Plasma levels of nitrate (NOx) increased from 22.8 +/- 14.4 to 41.8 +/- 26.6 mu mol/l (P = 0.007). Conclusions: A low dose of rIL2 has a negative inotropic effect that may be mediated by increased NO concentrations. It also reduces sympathetic activity as reflected in HRV parameters. (C) 2000 European Society of Cardiology. All rights reserved.

Original languageEnglish
Pages (from-to)167-173
Number of pages7
JournalEuropean Journal of Heart Failure
Volume2
Issue number2
Publication statusPublished - Jun-2000

Keywords

  • heart failure
  • interleukin-2
  • nitric oxide
  • heart rate variability
  • TUMOR-NECROSIS-FACTOR
  • ACTIVATED KILLER CELLS
  • NITRIC-OXIDE SYNTHASE
  • HEMODYNAMIC-CHANGES
  • CARDIAC MYOCYTES
  • HEART-FAILURE
  • CANCER
  • MYOCARDIUM
  • EXPRESSION
  • INFUSION

Cite this